Nature and is the result of a continuing collaboration between Army scientists and industry partners.
In addition to Marbug virus, the drug known as BCX4430 from BioCryst
Pharmaceuticals, Inc., showed promise against a broad range of other RNA
viruses, including the emerging viral pathogen Middle East respiratory
syndrome coronavirus (MERS-CoV), when tested in cell culture.
In the article “Protection against filovirus diseases by a novel
broad-spectrum nucleoside analog BCX4430,” the research revealed BCX4430
protected cynomolgous macaques (a nonhuman primate) from Marburg virus
infection when administered by injection up to 48 hours post-infection.
Also, the drug protected exposed guinea pigs from Marburg virus by the inhalation route.
The paper’s findings demonstrated how the drug interfered with the
internal “machinery” of Marburg virus, preventing it from replicating
its genetic material. Additional studies look to see whether that
48-hour therapeutic window can be extended.
With funding from the
Department of Health and Human Services (HHS)
National Institute of Allergy and Infectious Diseases
(NIAID), BioCryst plans to file investigational new drug (IND)
applications for intravenous and intramuscular BCX4430 for the treatment
of Marburg virus disease, as well as conducting Phase 1 human clinical
trials.